PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Burchert, A.* ; Bug, G.* ; Fritz, L.V.* ; Finke, J.* ; Stelljes, M.* ; Röllig, C.* ; Wollmer, E.* ; Wäsch, R.* ; Bornhäuser, M.* ; Berg, T.* ; Lang, F.* ; Ehninger, G.* ; Serve, H.* ; Zeiser, R.* ; Wagner, E.M.* ; Kröger, N.* ; Wolschke, C.* ; Schleuning, M.* ; Götze, K.S.* ; Schmid, C.* ; Crysandt, M.* ; Eßeling, E.* ; Wolf, D.* ; Wang, Y.* ; Böhm, A.* ; Thiede, C.* ; Haferlach, T.* ; Michel, C.* ; Bethge, W.* ; Wündisch, T.* ; Brandts, C.* ; Harnisch, S.* ; Wittenberg, M.* ; Hoeffkes, H.G.* ; Rospleszcz, S. ; Burchardt, A.* ; Neubauer, A.* ; Brugger, M. ; Strauch, K. ; Schade-Brittinger, C.* ; Metzelder, S.K.*

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN).

J. Clin. Oncol. 38, 2993-3002 (2020)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT.PATIENTS AND METHODSIn a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Trials Register: DRKS00000591), 83 adult patients with FLT3-ITD-positive AML in complete hematologic remission after HCT were randomly assigned to receive for 24 months either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 43) or placebo (n = 40 placebo). Relapse-free survival (RFS) was the primary endpoint of this trial. Relapse was defined as relapse or death, whatever occurred first.RESULTS With a median follow-up of 41.8 months, the hazard ratio (HR) for relapse or death in the sorafenib group versus placebo group was 0.39 (95% CI, 0.18 to 0.85; log-rank P = .013). The 24-month RFS probability was 53.3% (95% CI, 0.36 to 0.68) with placebo versus 85.0% (95% CI, 0.70 to 0.93) with sorafenib (HR, 0.256; 95% CI, 0.10 to 0.65; log-rank P = .002). Exploratory data show that patients with undetectable minimal residual disease (MRD) before HCT and those with detectable MRD after HCT derive the strongest benefit from sorafenib.CONCLUSION Sorafenib maintenance therapy reduces the risk of relapse and death after HCT for FLT3-ITD-positive AML.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
32.956
5.568
94
116
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Minimal Residual Disease; Versus-host-disease; Flt3 Gene; Therapeutic Target; Younger Adults; Aml; Chemotherapy; Multicenter; Proliferation; Inhibition
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0732-183X
e-ISSN 1527-7755
Zeitschrift Journal of Clinical Oncology - JCO
Quellenangaben Band: 38, Heft: 26, Seiten: 2993-3002 Artikelnummer: , Supplement: ,
Verlag American Society of Clinical Oncology
Verlagsort 2318 Mill Road, Ste 800, Alexandria, Va 22314 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Genetic Epidemiology (IGE)
POF Topic(s) 30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504100-001
Förderungen German Carreras Leukemia Foundation
DFG
Deutsche Forschungsgemeinschaft (DFG)
DOI 10.1200/JCO.19.03345
WOS ID WOS:000574584300002
PubMed ID 32673171
Erfassungsdatum 2020-07-28
[➜Korrektur melden]